Skip to main content
  1. Right Decisions
  2. Maternity & Gynaecology Guidelines
  3. Gynaecology
  4. Back
  5. Gynaecology guidelines
  6. Uterine Fibroids, Gynaecology (512)
Please update your RDS mobile app to version 4.7.1

We are pleased to advise that deep linking capability, enabling users to directly download individual mobile toolkits, has now been released on the RDS mobile app. When you install the update, you will see that each toolkit has a small QR code icon the header area beside the search icon – see screenshot below. Clicking on this icon will open up a window with a full-size QR code and the alternative of a short URL for sharing with users. Instructions are provided.

You may need to actively install the update to install RDS app version 4.7.1 to see this improvement. Installing this update is also strongly recommended to get the full benefits of the new contingency arrangements – specifically, that if the RDS website should fail, you will still be able to download new mobile app toolkits. 

To check your current RDS version, click on the three dots bottom right of the RDS app screen. This takes you to a “More” page where you will see the version number.  To install latest updates:

On iPhones – go to the Apple store, click on your profile icon top right, scroll down to see the apps waiting to be updated and update the RDS app.

On Android phones – these can vary, but try going to the Google Play store, click on your profile icon top right, click on “Manage apps and device”, select and update the RDS app.

Please get in touch with ann.wales3@nhs.scot with any questions.

Uterine Fibroids, Gynaecology (512)

Please report any inaccuracies or issues with this guideline using our online form

Uterine fibroids (leiomyomas) are common benign tumours found in 25% of women of reproductive age. They may be associated with heavy menstrual bleeding (HMB), pelvic pressure symptoms, subfertility and pregnancy problems.

The malignant potential of fibroids is extremely low (<1%) with leiomyosarcomas typically occuring in women above the age of 60years.

Resources

Use the button below to access this item.

Access this resource

Editorial Information

Last reviewed: 14/11/2023

Next review date: 31/10/2027

Author(s): Aradhana Khaund.

Version: 4

Co-Author(s): Claire Higgins.

Approved By: Gynaecology Clinical Governance Group

Document Id: 512

References

Fibroids: diagnosis and management. Lumsden MA, Hamoodi I, Gupta J, Hickey M, BMJ 2015;351:h4887

A review of evidence-based management of uterine fibroids K Younas, E Hadoura, F Majoko, A Bunkheila. The Obstetrician & Gynaecologist, 2016;18:33–42

NICE Clinical Knowledge Summaries, Management of Fibroids, May 2022

Liberty 1 & 2 Al-Hendy A et al. N Engl J Med 2021;38:630-642;

Liberty 3 Study Al-Hendy A, et al. Long-term Relugolix Combination Therapy for Symptomatic Uterine Leiomyomas. Obstet Gynecol. 2022 Dec 1;140(6):920-930.

Scottish Medicines Consortium (SMC) advice on new medicines.  SMC2442, relugolix 40mg, estradiol 1mg, norethisterone acetate 0.5mg film-coated tablets (Ryeqo®) May 2022.